The Anticipated Next Season of EGFR Inhibitors
A partir d'une revue de la littérature (28 essais identifiés), cette méta-analyse compare l'efficacité et la toxicité de trois thérapies ciblées anti EGFR (géfitinib, erlotinib et afatinib) pour le traitement des patients atteints d'un cancer métastatique du poumon non à petites cellules
Over the past decade, the story of EGFR inhibitors in lung cancer has unfolded much like a top cable TV drama with an iconic cast of characters (drugs, in this case) that we have gotten to know better and better with each passing season. We have come to recognize each character’s” attributes and flaws and watched the players strategically position themselves among the others through episodes filled with unexpected plot twists and suspenseful cliff-hangers...
The Oncologist 2015